DaVita Inc. today announced the launch of two groundbreaking initiatives aimed at deepening the medical community’s understanding of middle‑molecule removal and its potential to improve outcomes for patients with kidney failure. The initiatives—MODEL, a quality‑improvement study examining survival of U.S. patients treated with medium‑cut‑off dialyzers, and MEMOIRS, a prospective cohort study comparing patient‑reported outcomes between medium‑cut‑off and high‑flux dialyzers—will enroll roughly 9,000 adults with end‑stage kidney disease over the next two years.
The announcement highlights that DaVita is the first U.S. organization to generate data on middle‑molecule clearance, a key area that has been studied internationally but not in the U.S. population. By providing evidence that may influence future treatment protocols, the initiatives could enhance DaVita’s clinical reputation and potentially improve patient outcomes, which is central to the company’s value‑based care strategy.
DaVita’s commitment to innovation is underscored by its broader mission to deliver high‑quality, patient‑centered care across the kidney‑health continuum. The company serves approximately 283,100 patients at 3,175 outpatient dialysis centers worldwide, and the new studies align with its goal of reducing hospitalizations, improving mortality, and advancing the standard of care for all patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.